Iodixanol
Castration-resistant Prostate Cancer
Massachusetts General HospitalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
31 Active assets in the Castration-resistant Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Sichuan Baili Pharmaceutical Co., Ltd. | Phase 4 | BBB |
RADIUM RA-223 Bayer | Phase 4 | BB |
Abiraterone Acetate AstraZeneca | Phase 4 | BB |
Zoladex Bayer | Phase 3 | BB |
Seviteronel Innocrin Pharmaceutical | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Iodixanol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →